Tango Therapeutics, Inc.
TNGX
$1.28
-$0.095-6.91%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 42.07M | 43.38M | 42.51M | 37.23M | 36.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 42.07M | 43.38M | 42.51M | 37.23M | 36.53M |
| Cost of Revenue | 143.92M | 141.32M | 135.21M | 125.22M | 115.20M |
| Gross Profit | -101.85M | -97.94M | -92.70M | -87.99M | -78.67M |
| SG&A Expenses | 43.75M | 41.76M | 39.75M | 38.15M | 35.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 187.67M | 183.08M | 174.96M | 163.37M | 150.70M |
| Operating Income | -145.60M | -139.70M | -132.45M | -126.14M | -114.17M |
| Income Before Tax | -130.09M | -123.19M | -116.32M | -111.48M | -101.61M |
| Income Tax Expenses | 208.00K | 206.00K | 175.00K | 174.00K | 134.00K |
| Earnings from Continuing Operations | -130.30 | -123.40 | -116.49 | -111.65 | -101.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -130.30M | -123.40M | -116.49M | -111.65M | -101.74M |
| EBIT | -145.60M | -139.70M | -132.45M | -126.14M | -114.17M |
| EBITDA | -143.10M | -137.20M | -129.96M | -123.68M | -111.76M |
| EPS Basic | -1.20 | -1.17 | -1.13 | -1.13 | -1.10 |
| Normalized Basic EPS | -0.73 | -0.72 | -0.70 | -0.70 | -0.68 |
| EPS Diluted | -1.20 | -1.17 | -1.13 | -1.13 | -1.10 |
| Normalized Diluted EPS | -0.73 | -0.72 | -0.70 | -0.70 | -0.68 |
| Average Basic Shares Outstanding | 433.68M | 422.22M | 410.74M | 390.78M | 370.81M |
| Average Diluted Shares Outstanding | 433.68M | 422.22M | 410.74M | 390.78M | 370.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |